Evidence map›Paper›PMID 35760827›Full record

ArticleScientific reports2022

Saliva changes in composition associated to COVID-19: a preliminary study.

Alberto Muñoz-Prieto, Ivana Rubić, Juan Carlos Gonzalez-Sanchez, Josipa Kuleš, Silvia Martínez-Subiela, José Joaquín Cerón, Enrique Bernal, Alberto Torres-Cantero, María Rosario Vicente-Romero, Vladimir Mrljak and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Alberto Muñoz-PrietoClinic for Internal Diseases. Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000, Zagreb, Croatia.
Ivana RubićClinic for Internal Diseases. Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000, Zagreb, Croatia.
Juan Carlos Gonzalez-SanchezBioQuant, Heidelberg University, Im Neuenheimer Feld 267, Heidelberg, Germany.
Josipa KulešClinic for Internal Diseases. Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000, Zagreb, Croatia.
Silvia Martínez-SubielaInterdisciplinary Laboratory of Clinical Analysis, Regional Campus of International Excellence 'Campus Mare Nostrum', Interlab-UMU, University of Murcia, 30100, Murcia, Spain. silviams@um.es.
José Joaquín CerónInterdisciplinary Laboratory of Clinical Analysis, Regional Campus of International Excellence 'Campus Mare Nostrum', Interlab-UMU, University of Murcia, 30100, Murcia, Spain.
Enrique BernalUnit of Infectious Diseases, Hospital General Universitario Reina Sofía, Universidad de Murcia, 30003, Murcia, Spain.
Alberto Torres-CanteroPreventive Medicine, Hospital Clínico Universitario Virgen de La Arrixaca, IMIB, Universidad de Murcia, 30120, Murcia, Spain.
María Rosario Vicente-RomeroUnit of Microbiology, Hospital General Universitario Reina Sofía, Universidad de Murcia, 30003, Murcia, Spain.
Vladimir MrljakClinic for Internal Diseases. Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000, Zagreb, Croatia.
Asta TvarijonaviciuteInterdisciplinary Laboratory of Clinical Analysis, Regional Campus of International Excellence 'Campus Mare Nostrum', Interlab-UMU, University of Murcia, 30100, Murcia, Spain.
Universidad de Murcia · ESUniversity of Zagreb · HRHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2), is usually associated with a wide variety of clinical presentations from asymptomatic to severe cases. The use of saliva as a diagnostic and monitoring fluid has gained importance since it can be used to investigate the immune response and to direct quantification of antibodies against COVID-19. Additionally, the use of proteomics in saliva has allowed to increase  our understanding of the underlying pathophysiology of diseases, bringing new perspectives on diagnostics, monitoring, and treatment. In this work, we compared the salivary proteome of 10 patients with COVID-19, (five patients with mild and five patients with severe COVID-19) and ten control healthy patients. Through the application of proteomics, we have identified 30 proteins whose abundance levels differed between the COVID-19 groups and the control group. Two of these proteins (TGM3 and carbonic anhydrase-CA6) were validated by the measurement of gGT and TEA respectively, in 98 additional saliva samples separated into two groups: (1) COVID-19 group, integrated by 66 patients who tested positive for COVID-19 (2) control group, composed of 32 healthy individuals who did not show any sign of disease for at least four weeks and were negative for COVID-19 in RT-PCR. In the proteomic study there were observed upregulations in CAZA1, ACTN4, and ANXA4, which are proteins related to the protective response against the virus disturbance, and the upregulation of TGM3, that is correlated to the oxidative damage in pulmonary tissue. We also showed the downregulation in cystatins and CA6 that can be involved in the sensory response to stimulus and possibly related to the presence of anosmia and dysgeusia during the COVID-19. Additionally, the presence of FGB in patients with severe COVID-19 but not in mild COVID-19 patients could indicate a higher viral aggregation and activation in these cases. In conclusion, the salivary proteome in patients with COVID-19 showed changes in proteins related to the protective response to viral infection, and the altered sensory taste perception that occur during the disease. Moreover, gGT and TEA could be potential biomarkers of respiratory complications that can occurs during COVID 19 although further larger studies should be made to corroborate this.

Indexed as

COVID-19HumansProteomeProteomicsSalivaSARS-CoV-2TransglutaminasesProteomeTGM3 protein, humanTransglutaminases

Identifiers

PMID35760827
PMCPMC9237082
OpenAlexW4283706136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.